Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.

Scandinavian journal of gastroenterology - 1 Dec 2020

Oversoe Stine K, Clement Michelle S, Pedersen Michael H, Weber Britta, Aagaard Niels Kristian, Villadsen Gerda E, Grønbæk Henning, Hamilton-Dutoit Stephen J, Sorensen Boe S, Kelsen Jens

Abstract excerpt

BACKGROUND AND AIMS: Plasma circulating tumor DNA (ctDNA) with tumor-specific mutations is an attractive biomarker. The telomerase reverse transcriptase (TERT) C228T promoter mutation is the most prevalent tumor-associated mutation in hepatocellular carcinoma (HCC). We evaluated the presence and prognostic value of the TERT C228T mutation in plasma and tissue in a Danish HCC cohort. METHODS: We analyzed ctDNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Liver Neoplasms

Share to Liver physiology and pathology

Share to Mutation

Share to Prognosis

Share to Telomerase

Source

Identifiers

PMID: 33103505
DOI: 10.1080/00365521.2020.1837928

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.PMID 33103505Read ↗

Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinomaSemantic proximity Read ↗

Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.Semantic proximity Read ↗

Blood circulating C228T TERT gene promoter mutation is an independent factor for the prognosis of HBV-related hepatocellular carcinoma.Semantic proximity Read ↗

TERT promoter mutation predicts the prognosis value of patients with HBV- related HCC who underwent hepatectomySemantic proximity Read ↗

Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factorsSemantic proximity Read ↗

TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas.Semantic proximity Read ↗

Analysis of TERT promoter hotspot mutations using droplet digital PCR in hepatoblastoma and hepatocellular carcinoma.Semantic proximity Read ↗

TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomasSemantic proximity Read ↗

Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular CarcinomaSemantic proximity Read ↗

TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.Semantic proximity Read ↗

Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.Semantic proximity Read ↗

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.